DRUGS AND DRUG TARGETS
What is a drug target? And how many such targets are there? Here, we consider the nature of drug targets, and by classifying known drug substances on the basis of the discussed principles we provide an estimation of the total number of current drug targets.
Estimations of the total number of drug targets are presently dominated by analyses of the human genome, which are limited for various reasons, including the inability to infer the existence of splice variants or interactions between the encoded proteins from gene sequences alone, and the fact that the function of most of the DNA in the genome remains unclear. In 1997, when 100,000 protein-coding sequences were hypothesized to exist in the human genome, Drews and Ryser estimated the number of molecular targets 'hit' by all marketed drug substances to be only 482 .In 2002, after the sequencing of the human genome, others arrived at 8,000 targets of pharmacological interest, of which nearly 5,000 could be potentially hit by traditional drug substances, nearly 2,400 by antibodies and 800 by protein pharmaceuticals. And on the basis of ligand-binding studies, 399 molecular targets were identified belonging to 130 protein families, and 3,000 targets for small-molecule drugs were predicted to exist by extrapolations from the number of currently identified such targets in the human genome.
In summary, current target counts are of the order of 102, whereas estimations of the number of potential drug targets are an order of magnitude higher. In this paper, we consider the nature of drug targets, and use a classification based on this consideration, and a list of approved drug substances to estimate the number of known drug targets, in the following categories:
Type | Activity of drug | Drug examples |
Oxidoreductases | ||
Aldehyde dehydrogenase | Inhibitor | Disulfiram |
Monoamine oxidases (MAOs) | MAO-A inhibitor | Tranylcypromine, moclobemide |
MAO-B inhibitor | Tranylcypromine | |
Cyclooxygenases (COXs) | COX1 inhibitor | Acetylsalicylic acid, profens, acetaminophen and dipyrone (as arachidonylamides) |
COX2 inhibitor | Acetylsalicylic acid, profens, acetaminophen and dipyrone (as arachidonylamides) | |
Vitamin K epoxide reductase | Inhibitor | Warfarin, phenprocoumon |
Aromatase | Inhibitor | Exemestane |
Lanosterol demethylase (fungal) | Inhibitor | Azole antifungals |
Lipoxygenases | Inhibitor | Mesalazine |
5-lipoxygenase inhibitor | Zileuton | |
Thyroidal peroxidase | Inhibitor | Thiouracils |
Iodothyronine-5' deiodinase | Inhibitor | Propylthiouracil |
Inosine monophosphate dehydrogenase | Inhibitor | Mycophenolate mofetil |
HMG-CoA reductase | Inhibitor | Statins |
5 | Inhibitor | Finasteride, dutasteride |
Dihydrofolate reductase (bacterial) | Inhibitor | Trimethoprim |
Dihydrofolate reductase (human) | Inhibitor | Methotrexate, pemetrexed |
Dihydrofolate reductase (parasitic) | Inhibitor | Proguanil |
Dihydroorotate reductase | Inhibitor | Leflunomide |
Enoyl reductase (mycobacterial) | Inhibitor | Isoniazid |
Squalene epoxidase (fungal) | Inhibitor | Terbinafin |
Inhibitor | Amorolfin | |
Xanthine oxidase | Inhibitor | Allopurinol |
4-Hydroxyphenylpyruvate dioxygenase | Inhibitor | Nitisinone |
Ribonucleoside diphosphate reductase | Inhibitor | Hydroxycarbamide |
Transferases | ||
Protein kinase C | Inhibitor | Miltefosine |
Bacterial peptidyl transferase | Inhibitor | Chloramphenicol |
Catecholamine-O-methyltransferase | Inhibitor | Entacapone |
RNA polymerase (bacterial) | Inhibitor | Ansamycins |
Reverse transcriptases (viral) | Competitive inhibitors | Zidovudine |
Allosteric inhibitors | Efavirenz | |
DNA polymerases | Inhibitor | Acyclovir, suramin |
GABA transaminase | Inhibitor | Valproic acid vigabatrin |
Tyrosine kinases | PDGFR/ABL/KIT inhibitor | Imatinib |
EGFR inhibitor | Erlotinib | |
VEGFR2/PDGFR | Sunitinib | |
VEGFR2/PDGFR | Sorafenib | |
Glycinamide ribonucleotide formyl transferase | Inhibitor | Pemetrexed |
Phosphoenolpyruvate transferase (MurA, bacterial) | Inhibitor | Fosfomycin |
Human cytosolic branched-chain aminotransferase (hBCATc) | Inhibitor | Gabapentin |
Hydrolases (proteases) | ||
Aspartyl proteases (viral) | HIV protease inhibitor | Saquinavir, indinavir |
Hydrolases (serine proteases) | ||
Unspecific | Unspecific inhibitors | Aprotinine |
Bacterial serine protease | Direct inhibitor | |
Bacterial serine protease | Indirect inhibitor | Glycopeptides |
Bacterial lactamases | Direct inhibitor | Sulbactam |
Human antithrombin | Activator | Heparins |
Human plasminogen | Activator | Streptokinase |
Human coagulation factor | Activator | Factor IX complex, Factor VIII |
Human factor Xa | Inhibitor | Fondaparinux |
Hydrolases (metalloproteases) | ||
Human ACE | Inhibitor | Captopril |
Human HRD | Inhibitor | Cilastatin |
Human carboxypeptidase A (Zn) | Inhibitor | Penicillamine |
Human enkephalinase | Inhibitor | Racecadotril |
Hydrolases (other) | ||
26S proteasome | Inhibitor | Bortezomib |
Esterases | AChE inhibitor | Physostigmine |
AChE reactivators | Obidoxime | |
PDE inhibitor | Caffeine | |
PDE3 inhibitor | Amrinon, milrinone | |
PDE4 inhibitor | Papaverine | |
PDE5 inhibitor | Sildenafil | |
HDAC inhibitor | Valproic acid | |
HDAC3/HDAC7 inhibitor | Carbamezepine | |
Glycosidases (viral) | Zanamivir, oseltamivir | |
Glycosidases (human) | Acarbose | |
Lipases | Gastrointestinal lipases inhibitor | Orlistat |
Phosphatases | Calcineurin inhibitor | Cyclosporin |
Inositol polyphosphate phosphatase inhibitor | Lithium ions | |
GTPases | Rac1 inhibitor | 6-Thio-GTP (azathioprine metabolite) |
Phosphorylases | Bacterial C55-lipid phosphate dephosphorylase inhibitor | Bacitracin |
Lyases | ||
DOPA decarboxylase | Inhibitor | Carbidopa |
Carbonic anhydrase | Inhibitor | Acetazolamide |
Histidine decarboxylase | Inhibitor | Tritoqualine |
Ornithine decarboxylase | Inhibitor | Eflornithine |
Soluble guanylyl cyclase | Activator | Nitric acid esters, molsidomine |
Isomerases | ||
Alanine racemase | Inhibitor | D-Cycloserine |
DNA gyrases (bacterial) | Inhibitor | Fluoroquinolones |
Topoisomerases | Topoisomerase I inhibitor | Irinotecan |
Topoisomerase II inhibitor | Etoposide | |
Inhibitor | Amorolfin | |
Ligases (also known as synthases) | ||
Dihydropteroate synthase | Inhibitor | Sulphonamides |
Thymidylate synthase (fungal and human) | Inhibitor | Fluorouracil |
Thymidylate synthase (human) | Inhibitor | Methotrexate, pemetrexed |
Phosphofructokinase | Inhibitor | Antimony compounds |
mTOR | Inhibitor | Rapamycin |
Haem polymerase (Plasmodium) | Inhibitor | Quinoline antimalarials |
1,3- | Inhibitor | Caspofungin |
Glucosylceramide synthase | Inhibitor | Miglustat |
TABLE 2 | Receptors
Type | Activity of drug | Drug examples |
Direct ligand-gated ion channel receptors | ||
GABAA receptors | Barbiturate binding site agonists | Barbiturate |
Benzodiazepine binding site agonists | Benzodiazepines | |
Benzodiazepine binding site antagonists | Flumazenil | |
Acetylcholine receptors | Nicotinic receptor agonists | Pyrantel (of Angiostrongylus), levamisole |
Nicotinic receptor stabilizing antagonists | Alcuronium | |
Nicotinic receptor depolarizing antagonists | Suxamethonium | |
Nicotinic receptor allosteric modulators | Galantamine | |
Glutamate receptors (ionotropic) | NMDA subtype antagonists | Memantine |
NMDA subtype expression modulators | Acamprosate | |
NMDA subtype phencyclidine binding site antagonists | Ketamine | |
G-protein-coupled receptors | ||
Acetylcholine receptors | Muscarinic receptor agonists | Pilocarpine |
Muscarinic receptor antagonists | Tropane derivatives | |
Muscarinic receptor M3 antagonists | Darifenacine | |
Adenosine receptors | Agonists | Adenosine |
Adenosine A1 receptor agonists | Lignans from valerian | |
Adenosine A1receptor antagonists | Caffeine, theophylline | |
Adenosine A2A receptor antagonists | Caffeine, theophylline | |
Adrenoceptors | Agonists | Adrenaline, noradrenaline, ephedrine |
Xylometazoline | ||
Ergotamine | ||
Methyldopa (as methylnoradrenaline) | ||
Isoprenaline | ||
Propranolol, atenolol | ||
Salbutamol | ||
Propranolol | ||
Angiotensin receptors | AT1-receptors antagonists | Sartans |
Calcium-sensing receptor | Agonists | Strontium ions |
Allosteric activators | Cinacalcet | |
Cannabinoid receptors | CB1 - and CB2-receptors agonists | Dronabinol |
Cysteinyl-leukotriene receptors | Antagonists | Montelukast |
Dopamine receptors166 | Dopamine receptor subtype direct agonists | Dopamine, levodopa |
D2, D3 and D4 agonists | Apomorphine | |
D2, D3 and D4 antagonists | Chlorpromazine, fluphenazine, haloperidol, metoclopramide, ziprasidone | |
Endothelin receptors (ETA, ETB) | Antagonists | Bosentan |
GABAB receptors | Agonists | Baclofen |
Glucagon receptors | Agonists | Glucagon |
Glucagon-like peptide-1 receptor | Agonists | Exenatide |
Histamine receptors | H1-antagonists | Diphenhydramine |
H2-antagonists | Cimetidine | |
Morphine, buprenorphine | ||
Naltrexone | ||
Buprenorphine | ||
Neurokinin receptors | NK1 receptor antagonists | Aprepitant |
Prostanoid receptors | Agonists | Misoprostol, sulprostone, iloprost |
Prostamide receptors | Agonists | Bimatoprost |
Purinergic receptors | P2Y12 antagonists | Clopidogrel |
Serotonin receptors | Subtype-specific (partial) agonists | Ergometrine, ergotamine |
5-HT1A partial agonists | Buspirone | |
5-HT1B/1D agonists | Triptans | |
5-HT2A antagonists | Quetiapine, ziprasidone | |
5-HT3 antagonists | Granisetron | |
5-HT4 partial agonists | Tegaserode | |
Vasopressin receptors184 | Agonists | Vasopressin |
V1 agonists | Terlipressin | |
V2 agonists | Desmopressin | |
OT agonists | Oxytocin | |
OT antagonists | Atosiban | |
Cytokine receptors | ||
Class I cytokine receptors | Growth hormone receptor antagonists | Pegvisomant |
Erythropoietin receptor agonists | Erythropoietin | |
Granulocyte colony stimulating factor agonists | Filgrastim | |
Granulocyte-macrophage colony stimulating factor agonists | Molgramostim | |
Interleukin-1 receptor antagonists | Anakinra | |
Interleukin-2 receptor agonists | Aldesleukin | |
TNF | Mimetics (soluble) | Etanercept |
Integrin receptors | ||
Glycoprotein IIb/IIIa receptor | Antagonists | Tirofiban |
Receptors associated with a tyrosine kinase | ||
Insulin receptor | Direct agonists | Insulin |
Insulin receptor | Sensitizers | Biguanides |
Nuclear receptors (steroid hormone receptors) | ||
Mineralocorticoid receptor196 | Agonists | Aldosterone |
Antagonists | Spironolactone | |
Glucocorticoid receptor | Agonists | Glucocorticoids |
Progesterone receptor | Agonists | Gestagens |
Oestrogen receptor199 | Agonists | Oestrogens |
(Partial) antagonists | Clomifene | |
Antagonists | Fulvestrant | |
Modulators | Tamoxifen, raloxifene | |
Testosterone | ||
Antagonists | Cyproterone acetate | |
Agonists | Retinoids | |
ACTH receptor agonists | Agonists | Tetracosactide (also known as cosyntropin) |
Nuclear receptors (other) | ||
Retinoic acid receptors RAR | Isotretinoin | |
RAR | Adapalene, isotretinoin | |
RAR | Adapalene, isotretinoin | |
Peroxisome proliferator-activated receptor (PPAR) | PPAR | Fibrates |
PPAR | Glitazones | |
Thyroid hormone receptors | Agonists | L-Thyroxine |
Download file
If the slide opens in your browser, select "File > Save As" to save
TABLE 3 | Ion channels
|
Type | Activity of drug | Drug examples |
Voltage-gated Ca2+ channels | ||
General | Inhibitor | Oxcarbazepine |
In Schistosoma sp. | Inhibitor | Praziquantel |
L-type channels | Inhibitor | Dihydropyridines, diltiazem, lercanidipine, pregabalin, verapamil |
T-type channels | Inhibitor | Succinimides |
K+ channels225 | ||
Epithelial K+ channels | Opener Inhibitor | Diazoxide, minoxidilNateglinide, sulphonylureas |
Voltage-gated K+ channels | Inhibitor | Amiodarone |
Na+ channels | ||
Epithelial Na+ channels (ENaC)231 | Inhibitor | Amiloride, bupivacaine, lidocaine, procainamide, quinidine |
Voltage-gated Na+ channels | Inhibitor | |
Ryanodine-inositol 1,4,5-triphosphate receptor Ca2+ channel (RIR-CaC) family | ||
Ryanodine receptors | Inhibitor | Dantrolene |
Transient receptor potential Ca2+ channel (TRP-CC) family | ||
TRPV1 receptors | Inhibitor | Acetaminophen (as arachidonylamide) |
Cl- channels243 | ||
Cl-channel | Inhibitor (mast cells) Opener (parasites) | Cromolyn sodium Ivermectin |
·
TABLE 4 | Transport proteins (uniporters, symporters and antiporters)
Type | Activity of drug | Drug examples |
Cation-chloride cotransporter (CCC) family247 | Thiazide-sensitive NaCl symporter, human inhibitor | Thiazide diuretics |
Bumetanide-sensitive NaCl/KCl symporters, human inhibitor | Furosemide | |
Na+/H+ antiporters | Inhibitor | Amiloride, triamterene |
Proton pumps | Ca2+-dependent ATPase (PfATP6; Plasmodia) inhibitor | Artemisinin and derivatives |
H+/K+-ATPase | Inhibitor | Omeprazole |
Na+/K+ ATPase | Inhibitor | Cardiac glycosides |
Eukaryotic (putative) sterol transporter (EST) family | Niemann-Pick C1 like 1 (NPC1L1) protein inhibitor | Ezetimibe |
Serotonin/Na+ symporter inhibitor | Cocaine, tricyclic antidepressants, paroxetine | |
Noradrenaline/Na+ symporter inhibitor | Bupropion, venlafaxine | |
Dopamine/Na+ symporter inhibitor | Tricyclic antidepressants, cocaine, amphetamines | |
Vesicular monoamine transporter inhibitor | Reserpine |
|
TABLE 5 | DNA/RNA and the ribosome
Target | Activity of drug | Example drugs |
Nucleic acids | ||
DNA and RNA265 | Alkylation | Chlorambucil, cyclophosphamide, dacarbazine |
Complexation | Cisplatin | |
Intercalation | Doxorubicin | |
Oxidative degradation | Bleomycin | |
Strand breaks | Nitroimidazoles | |
RNA | Interaction with 16S-rRNA | Aminoglycoside antiinfectives |
Interaction with 23S-rRNA | Macrolide antiinfectives | |
23S-rRNA/tRNA/2-polypeptide complex | Oxazolidinone antiinfectives | |
Spindle | Inhibition of development | Vinca alkaloids |
Inhibition of desaggregation | Taxanes | |
Inhibition of mitosis | — | Colchicine |
Ribosome | ||
30S subunit (bacterial) | Inhibitors | Tetracyclines |
50S subunit (bacterial) | Inhibitors |
TABLE 6 | Targets of monoclonal antibodies
|
Target | Agent |
Vascular endothelial growth factor | Bevacizumab |
Lymphocyte function-associated antigen 1 | Efalizumab |
Epidermal growth factor receptor | Cetuximab |
Human epidermal growth factor receptor 2 | Trastuzumab |
Immunoglobulin E (IgE) | Omalizumab |
CD-3 | Muromonab-CD3 |
CD-20 | Rituximab, ibritumomab tiuxetan, 131I-tositumomab |
CD-33 | Gemtuzumab |
CD-52 | Alemtuzumab |
F protein of RSV subtypes A and B | Palivizumab |
CD-25 | Basiliximab, daclizumab |
Tumour-necrosis factor- | Adalimumab, infliximab |
Glycoprotein IIb/IIIa receptor | Abciximab |
Natalizumab |
·
TABLE 7 | Various physicochemical mechanisms
|
Mechanism | Agent |
Ion exchange | Fluoride |
Acid binding | Magnesium hydroxide, aluminium hydroxide |
Adsorptive | Charcoal, colestyramine |
Adstringent | Bismuth compounds |
Surface-active | Simeticone, chlorhexidine, chloroxylene |
Surface-active on cell membranes | Coal tar |
Surface-active from fungi | Nystatin, amphotericin B |
Mucosal irritation | Anthrones, anthraquinones |
Osmotically active | Lactulose, dextran 70, polygeline, glucose, electrolyte solutions, mannitol |
Water binding | Urea, ethanol |
UV absorbant | 4-Aminobenzoic acid derivatives |
Reflective | Zinc oxide, titanium dioxide |
Oxidative | Tannines, polyphenoles, dithranol, polyvidon iodide, silver nitrate, hypochlorite, permanganate, benzoylperoxide, nitroimidazoles, nitrofuranes, temoporfin (mainly via singlet oxygen, cytostatic drug), verteporfin (mainly via singlet oxygen, ophthalmic drug) |
Reduce disulphide bridges | D-Penicillamine, N-acetyl-cysteine |
Complexing agents | Al3+, arsenic compounds |
Salt formation | Sevelamer |
Modification of tertiary structure | Enfuvirtide (from HIV glycoprotein 41) |
Good one.You may also like to read this NegosyongPinoy.info
ReplyDelete
ReplyDeleteI was diagnosed as HEPATITIS B carrier in 2013 with fibrosis of the
liver already present. I started on antiviral medications which
reduced the viral load initially. After a couple of years the virus
became resistant. I started on HEPATITIS B Herbal treatment from
ULTIMATE LIFE CLINIC (www.ultimatelifeclinic. com) in March, 2020. Their
treatment totally reversed the virus. I did another blood test after
the 6 months long treatment and tested negative to the virus. Amazing
treatment! This treatment is a breakthrough for all HBV carriers.